Proteomic investigation of treatment with medicinal mushroom supplement Agarikon.1® in advanced colorectal cancer animal model

ABSTRACT: Colorectal cancer (CRC) is the third most frequent cancer type in both males and females, with about 35% of patients being diagnosed in stage IV metastatic disease. Despite advancements in treatment, life expectancy in patients with metastatic disease is low. Due to frequent drug resistance during conventional and targeted cancer treatments, the development and testing of multi-target therapies is an important objective. Medicinal mushrooms specific compound isolates as well as complex extract mixtures have been studied in depth, and many mushroom species have been proven to be non-toxic multi-target inhibitors of specific oncogenic pathways, as well as potent immunomodulators. In this study, we have performed a tandem mass tags qualitative and quantitative proteomic analyses of CT26.WT colon cancer tumor tissues from Balb/c mice treated with proprietary medicinal mushroom extract Agarikon.1®, with or without 5-fluorouracil.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Cell Culture, Colon

DISEASE(S): Colon Cancer

SUBMITTER: Anita Horvatic  

LAB HEAD: Peter David Eckersall

PROVIDER: PXD018827 | Pride | 2020-10-27

REPOSITORIES: Pride